All In Biotech

Drug Trial Radar · NCT05440708

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

REVERT- Liver Cancer: A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

193

Planned (sponsor's estimate)

Start

Mar 23, 2023

Primary completion

May 25, 2027

Study completion Jul 20, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of TTI-101 as a single agent. The primary objectives of Cohort A Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent at the RP2D to participants with locally advanced or metastatic, and unresectable HCC and to assess the preliminary efficacy of TTI-101 as a single agent in participants with locally advanced or metastatic, and unresectable HCC. The secondary objectives of Cohort A Phase 2 are to assess response, progression, survival, and pharmacokinetics. The primary objectives of Cohorts B and C Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) to participants with locally advanced or metastatic, or unresectable HCC and to determine the MTD and/or RP2D of TTI-101 when used in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C). The primary objectives of Cohorts B and C Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) at the RP2D to participants with locally advanced or metastatic, and unresectable HCC and to assess the preliminary efficacy of TTI-101 in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) to participants with locally advanced or metastatic, and unresectable HCC. The secondary objectives of Cohorts B and C Phase 2 are to assess response, progression, survival, and pharmacokinetics.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • TTI-101Drug

    Oral tablet

  • PembrolizumabDrug

    Intravenous (IV) infusion

  • AtezolizumabDrug

    Intravenous (IV) infusion

  • BevacizumabDrug

    Intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AE)Time frame: Up to approximately 20 months
  2. Incidence of Serious Adverse Events (SAE)Time frame: Up to approximately 18 months
  3. Phase 2: Overall Response Rate (ORR) to TTI-101Time frame: Up to approximately 18 months

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • The Kirklin Clinic of University of Alabama Birmingham Hospital

    Birmingham, Alabama · Completed

  • University of California San Diego

    La Jolla, California · Completed

  • Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • University of California Irvine Medical Center

    Orange, California · Recruiting

  • University of Colorado Hospital - Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Georgetown Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia · Completed

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • The Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan · Completed

  • Washington University in St. Louis

    St Louis, Missouri · Recruiting

  • Memorial Sloan Kettering Cancer Center - New York

    New York, New York · Recruiting

  • Cleveland Clinic Lerner College of Medicine

    Cleveland, Ohio · Completed

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma · Recruiting

  • Harold C. Simmons Comprehensive Cancer Center

    Dallas, Texas · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • DHR Health Institute for Research and Development

    McAllen, Texas · Recruiting

  • University of Texas Health Science Center - San Antonio

    San Antonio, Texas · Recruiting

  • Virginia Mason Medical Center

    Seattle, Washington · Recruiting

  • Summit Cancer Centers - North Spokane

    Spokane, Washington · Recruiting

  • Froedtert and Medical College of Wisconsin

    Milwaukee, Wisconsin · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.